Arcturus Therapeutics Holdings Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Arcturus Therapeutics Holdings Inc. (ARCT)

If you purchased or held Arcturus Therapeutics Holdings securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings is a biotechnology company focused on developing RNA-based medicines, including mRNA therapeutics and vaccines.

The company’s pipeline has centered on respiratory diseases, with a particular emphasis on cystic fibrosis through its ARCT-032 program.

Potential Concerns Under Investigation

Lawyers are investigating whether Arcturus Therapeutics Holdings may have made misleading statements or omitted material facts about the efficacy of its ARCT-032 cystic fibrosis program and related communications about clinical progress and cash runway.

In early 2025 the company told investors that a refocused pipeline extended its cash position through 2028 and identified ARCT-032 as a core program.

Legal professionals may examine whether, during the months leading up to this disclosure, Arcturus Therapeutics Holdings provided investors with an overly optimistic view of the ARCT-032 program while omitting important negative information. For example, on May 12, 2025, management stated that the team was “working diligently to provide meaningful Phase 2 interim data mid-year”.

Similarly, on August 11, 2025, management reiterated progress and timing for Phase 2 data for ARCT-032. However, on October 22, 2025 the company issued disappointing interim Phase 2 results; coverage reported no meaningful improvement in FEV1 after 28 days.

On this news, the stock fell approximately 50%, moving from roughly $23.16 on October 21 to $11.54 on the following day, causing significant harm to investors.

The investigation may also focus on whether the upbeat statements about ARCT-032’s timeline, safety, and early trends, while omitting the emerging efficacy problems, rendered prior communications misleading.

Your Rights and Next Steps

This is an active investigation into potential violations of federal securities laws by Arcturus Therapeutics Holdings. Lawyers are reviewing whether investors may have been misled by statements or omissions regarding the ARCT-032 program’s efficacy and the company’s public communications.

If you purchased Arcturus Therapeutics Holdings securities between January 2025 and October 21, 2025 and suffered financial losses, you may have the right to participate in this investigation. Investors are encouraged to gather and retain records of their purchases, sales, and account statements for this period.

By joining the investigation, investors may be able to seek compensation for losses suffered as a result of any potential securities law violations.

Lawyers are ready to help investors understand their rights and guide them through the process. Participation in the investigation is confidential and does not obligate investors to take any further action unless they choose to do so.

You May Be Entitled to Compensation

Securities investigations are time-sensitive. If you purchased or acquired Arcturus Therapeutics Holdings securities between January 2025 and October 21, 2025, you may be eligible to join any potential class action and pursue compensation.

To protect your rights and learn more about your options, complete the form below to join the investigation.